Enteric Softgel Capsules Market Size to Reach USD 5.81 Billion by 2034
The global enteric softgel capsules market size is calculated at USD 3.85 billion in 2024, grow to USD 4.01 billion in 2025, and is projected to reach around USD 5.81 billion by 2034, growing at a CAGR of 4.2% from 2025 to 2034. The market is growing due to increasing demand for targeted drug delivery systems that protect active ingredients from stomach acid. Additionally, the rising prevalence of gastrointestinal disorders is driving their adoption.
The enteric softgel capsule is a soft gelatin capsule coated with an enteric layer that prevents it from dissolving in the stomach acid, allowing it to release its contents in the intestine. It is used acid acid-sensitive drugs and ensures targeted delivery. The enteric softgel capsule market is evolving rapidly due to advancements in coating technologies, rising demand for targeted drug delivery, and the growing popularity of plant-based capsules. Increased use of nutraceuticals for protecting sensitive ingredients like probiotics and omega-3s is also driving growth. Additionally, the shift toward personalized medicine and the expansion in emerging markets are contributing to the market's development. These factors collectively enhance patient compliance and improve the effectiveness of medications.
Artificial Intelligence is transforming the enteric softgel capsules market by enhancing formulation development, improving quality control, and accelerating drug discovery. AI helps identify optimal ingredient combinations and coating materials, ensuring better stability and targeted release. It also enables real-time monitoring during manufacturing for consistent product quality. Additionally, AI supports personalized medicine by tailoring softgel formulations to individual needs and improves market forecasting, helping companies better manage demand and inventory. This leads to greater efficiency and innovation in the industry.
| Report Coverage | Details |
| Market Size in 2025 | USD 4.01 Billion |
| Market Size by 2034 | USD 5.81 Billion |
| Growth Rate From 2025 to 2034 | CAGR of 4.2% |
| Base Year | 2024 |
| Forecast Period | 2025-2034 |
| Segments Covered | By Application, By Distribution Channel, By Region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional scope | North America; Europe; Asia Pacific; Latin America; MEA |
| Key Companies Profiled | Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Cube Biotech GmbH, Danaher, Merck KGaA, Norgen Biotek Corp., Promega Corporation, QIAGEN, Takara Bio. Inc., Thermo Fisher Scientific, Inc. |
Driver
Rising Demand for Targeted and Controlled Drug Delivery
The increasing preference for and controlled drug delivery is a major factor fueling the growth of the enteric softgel capsule market. These capsules are designed to bypass the stomach and dissolve in the intestine, ensuring precise and effective delivery of active ingredients. BY protecting drugs from gastric degradation and reducing adverse effects, they enhance therapeutic results and support better adherence to treatment, especially for long-term and specialized medication used in both pharmaceutical and nutraceutical applications.
High Production Cost and Complex Manufacturing Process
The production of enteric softgel capsules involves sophisticated techniques and high-grade materials, which make the process costly and technically demanding. Achieving accurate pH-sensitive coating and maintaining product consistency requires advanced machinery and skilled personnel. Moreover, the need for strict regulatory compliance and controlled manufacturing environments adds to operational complexity. These challenges increase overall costs and limit the ability of small and mid-sized manufacturers to compete, thereby acting as a barrier to broader market expansion.
Growing Demand for Plant-based and Vegan Capsule Alternatives
The increasing shift towards a plant-based lifestyle is creating new growth avenues in the enteric softgel capsule market. Consumers are becoming more conscious about the origin of health supplements, preferring options that align with vegan, vegetarian, and religious dietary requirements. This trend is encouraging for softgel production. By offering plant-derived enteric capsules, companies can expand their market reach, meet clean-label demands, and strengthen their position in the evolving nutraceutical and pharmaceutical landscape.
How will the Health Supplements Segment Dominate the Enteric Softgel Capsules Market in 2024?
The health supplements segment leads the market due to increasing health consciousness and the widespread use of enteric softgel capsules for delivering nutrients that are sensitive to stomach acid. These capsules help ensure active ingredients reach the intestine intact, improving their effectiveness. The convenience, ease of swallowing, and demand for high-quality dietary products are pushing more consumers towards softgel-based supplements, which is driving both strong revenue performance and rapid growth in the market.
Why Did the Pharmacy and Drug Store Segment Dominate the Market in 2024?
The pharmacy and drug store segment captured the largest market share for enteric softgel capsules due to their strong distribution networks, frequent consumer footfall, and the ability to provide both prescription and non-prescription products. These outlets are often the first point of access for health solutions, making them ideal for the sale of supplements and medications in enteric softgel form. Their established relationships with healthcare providers and consumers further their role in driving sales within this market.
The online provider segment is growing at the fastest rate due to the rising adoption of e-commerce platforms for healthcare purchases and the increasing use of smartphones and internet access. Consumers are drawn to the ease of ordering supplements and medications online, often with doorstep delivery and attractive discounts. The availability of a wide range of enteric softgel products and the shift towards digital health solutions are further accelerating the growth of the market.
Regional Insights
How is North America Contributing to the Expansion of the Enteric Softgel Capsules Market?
North America dominated the market due to its advanced healthcare infrastructure, substantial healthcare spending, and high consumer awareness regarding health and wellness. The region's strong pharmaceutical and nutraceutical industries, coupled with a growing aging population and prevalence of chronic diseases, have increased demand for targeted drug delivery systems like enteric softgels. Additionally, the presence of major capsule manufacturers and favorable regulatory environments has further solidified North America's leading position in the market.
How is Asia-Pacific approaching the enteric Softgel Capsules Market in 2024?
Asia-Pacific is set to grow at the fastest CAGR in the market due to rising healthcare needs, rapid urbanization, and increasing investment in pharmaceutical manufacturing. The growing middle-class population, along with a shift toward preventive healthcare and dietary supplements, is boosting demand for innovative drug delivery formats. Additionally, favorable government initiatives and expanding online healthcare retail in countries like India, China, and Southeast Asia are further accelerating regional market growth.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc. has segmented the Enteric Softgel Capsules Market.
By Application
By Distribution Channel
By Regional
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers